半胱氨酰白三烯受体拮抗剂在Guidelines中的地位(修改后).pptVIP

* * TABLE II. Outcome frequencies in the 12 months after dispensing the controller medication in a subset of subjects who were continuously enrolled for the 12 months after controller medication dispensing: the number of subjects who experienced 1 or more ED visits, hospitalizations, oral courses of oral corticosteroids In subjects who metcriteria for continuous enrollment, 21% of patients in TennCare Medicaid who filled an ICS experienced an exacerbation compared with 17% of patients who filled an ICS-LABA or 14% who filled an LTRA (P 0 .001). * * Figure 3. Algorithm of preventive pharmaco